Papzimeos is the first immunotherapy approved for recurrent respiratory papillomatosis, a rare lung disorder involving the ...

The Department of Health and Human Services’ mRNA pullback only applies to their use in upper respiratory disease, according ...

The move comes after Robert F. Kennedy Jr. received pressure from the Children’s Health Defense, an anti-vaccine non-profit ...

As Trump has pressured drugmakers to lower the cost of medicines in the U.S., the pharma industry has coalesced behind a ...

The death was linked to acute kidney injury in a patient who had a single kidney remaining and a “complex medical history,” ...

After two patients who received the investigational CDC7 blocker died, pushing forward with SGR-2921’s development would be ...

WARN notices provide a heads up that staff will soon be unemployed, but the act that mandates them has some nuances. An ...

The layoffs will not spare Generation’s R&D team, which will initially be retained while the biotech completes its strategic ...

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...

The HHS secretary recently canceled $500 million worth of BARDA contracts around mRNA vaccine research. But the U.S.

Citing other priorities—such as the upcoming U.S.-Russia summit—four anonymous sources claim that pharma tariffs could still ...

In this episode of Denatured, BioSpace’s head of insights Lori Ellis discusses the ‘enormous implications’ of patent policy ...